Cargando…
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors
BACKGROUND: Epithelial ovarian carcinomas encompass a heterogeneous group of diseases with a poor 5-year survival rate. Serous carcinoma is the most common type. Most FDA-approved serum tumor markers are glycoproteins. These glycoproteins on cell surface or shed into the bloodstream could serve as t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424371/ https://www.ncbi.nlm.nih.gov/pubmed/28491011 http://dx.doi.org/10.1186/s12014-017-9152-2 |
_version_ | 1783235120571875328 |
---|---|
author | Li, Qing Kay Shah, Punit Tian, Yuan Hu, Yingwei Roden, Richard B. S. Zhang, Hui Chan, Daniel W. |
author_facet | Li, Qing Kay Shah, Punit Tian, Yuan Hu, Yingwei Roden, Richard B. S. Zhang, Hui Chan, Daniel W. |
author_sort | Li, Qing Kay |
collection | PubMed |
description | BACKGROUND: Epithelial ovarian carcinomas encompass a heterogeneous group of diseases with a poor 5-year survival rate. Serous carcinoma is the most common type. Most FDA-approved serum tumor markers are glycoproteins. These glycoproteins on cell surface or shed into the bloodstream could serve as therapeutic targets as well as surrogates of tumor. In addition to glycoprotein expressions, the analysis of protein glycosylation occupancy could be important for the understanding of cancer biology as well as the identification of potential glycoprotein changes in cancer. In this study, we used an integrated proteomics and glycoproteomics approach to analyze global glycoprotein abundance and glycosylation occupancy for proteins from high-grade ovarian serous carcinoma (HGSC) and serous cystadenoma, a benign epithelial ovarian tumor, by using LC–MS/MS-based technique. METHODS: Fresh-frozen ovarian HGSC tissues and benign serous cystadenoma cases were quantitatively analyzed using isobaric tags for relative and absolute quantitation for both global and glycoproteomic analyses by two dimensional fractionation followed by LC–MS/MS analysis using a Orbitrap Velos mass spectrometer. RESULTS: Proteins and N-linked glycosite-containing peptides were identified and quantified using the integrated global proteomic and glycoproteomic approach. Among the identified N-linked glycosite-containing peptides, the relative abundances of glycosite-containing peptide and the glycoprotein levels were compared using glycoproteomic and proteomic data. The glycosite-containing peptides with unique changes in glycosylation occupancies rather than the protein expression levels were identified. CONCLUSION: In this study, we presented an integrated proteomics and glycoproteomics approach to identify changes of glycoproteins in protein expression and glycosylation occupancy in HGSC and serous cystadenoma and determined the changes of glycosylation occupancy that are associated with malignant and benign tumor tissues. Specific changes in glycoprotein expression or glycosylation occupancy have the potential to be used in the discrimination between benign and malignant epithelial ovarian tumors and to improve our understanding of ovarian cancer biology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-017-9152-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5424371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54243712017-05-10 An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors Li, Qing Kay Shah, Punit Tian, Yuan Hu, Yingwei Roden, Richard B. S. Zhang, Hui Chan, Daniel W. Clin Proteomics Research BACKGROUND: Epithelial ovarian carcinomas encompass a heterogeneous group of diseases with a poor 5-year survival rate. Serous carcinoma is the most common type. Most FDA-approved serum tumor markers are glycoproteins. These glycoproteins on cell surface or shed into the bloodstream could serve as therapeutic targets as well as surrogates of tumor. In addition to glycoprotein expressions, the analysis of protein glycosylation occupancy could be important for the understanding of cancer biology as well as the identification of potential glycoprotein changes in cancer. In this study, we used an integrated proteomics and glycoproteomics approach to analyze global glycoprotein abundance and glycosylation occupancy for proteins from high-grade ovarian serous carcinoma (HGSC) and serous cystadenoma, a benign epithelial ovarian tumor, by using LC–MS/MS-based technique. METHODS: Fresh-frozen ovarian HGSC tissues and benign serous cystadenoma cases were quantitatively analyzed using isobaric tags for relative and absolute quantitation for both global and glycoproteomic analyses by two dimensional fractionation followed by LC–MS/MS analysis using a Orbitrap Velos mass spectrometer. RESULTS: Proteins and N-linked glycosite-containing peptides were identified and quantified using the integrated global proteomic and glycoproteomic approach. Among the identified N-linked glycosite-containing peptides, the relative abundances of glycosite-containing peptide and the glycoprotein levels were compared using glycoproteomic and proteomic data. The glycosite-containing peptides with unique changes in glycosylation occupancies rather than the protein expression levels were identified. CONCLUSION: In this study, we presented an integrated proteomics and glycoproteomics approach to identify changes of glycoproteins in protein expression and glycosylation occupancy in HGSC and serous cystadenoma and determined the changes of glycosylation occupancy that are associated with malignant and benign tumor tissues. Specific changes in glycoprotein expression or glycosylation occupancy have the potential to be used in the discrimination between benign and malignant epithelial ovarian tumors and to improve our understanding of ovarian cancer biology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-017-9152-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-10 /pmc/articles/PMC5424371/ /pubmed/28491011 http://dx.doi.org/10.1186/s12014-017-9152-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Li, Qing Kay Shah, Punit Tian, Yuan Hu, Yingwei Roden, Richard B. S. Zhang, Hui Chan, Daniel W. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title | An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title_full | An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title_fullStr | An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title_full_unstemmed | An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title_short | An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
title_sort | integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424371/ https://www.ncbi.nlm.nih.gov/pubmed/28491011 http://dx.doi.org/10.1186/s12014-017-9152-2 |
work_keys_str_mv | AT liqingkay anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT shahpunit anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT tianyuan anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT huyingwei anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT rodenrichardbs anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT zhanghui anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT chandanielw anintegratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT liqingkay integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT shahpunit integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT tianyuan integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT huyingwei integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT rodenrichardbs integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT zhanghui integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors AT chandanielw integratedproteomicandglycoproteomicapproachuncoversdifferencesinglycosylationoccupancyfrombenignandmalignantepithelialovariantumors |